ERBB2 and breast carcinoma: Furthermore, the immunohistochemical staining results and subsequent data analysis revealed that CYB561 exhibited a higher expression level and was associated with a poorer prognosis specifically in HER2-positive breast cancer (BRCA) compared to other molecular subtypes of BRCA.